Je Yeol Cho

Title: Je Yeol Cho: Innovator in Targeted Cancer Therapy

Introduction

Je Yeol Cho is a prominent inventor based in Daegu, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and patented technologies. His work focuses on developing specific peptides that can target cancer cells effectively.

Latest Patents

Je Yeol Cho holds a patent for a specific peptide binding to glypican-3. This peptide is designed to bind specifically to glypican-3, which is overexpressed in various carcinoma cells. The amino acid sequence represented by SEQ ID NO:1 is crucial for its function. Glypican-3 is known to be overexpressed in malignant tumors, including hepatocellular carcinoma, melanoma, and germ cell tumors. The targeting peptide can be utilized in both the diagnosis and treatment of tumors. It allows for more accurate detection of small tumors compared to conventional methods. Additionally, the treatment method using this peptide can selectively remove carcinoma cells without damaging surrounding normal tissues.

Career Highlights

Je Yeol Cho is affiliated with the Kyungpook National University Industry-Academic Cooperation Foundation. His work at this institution has been instrumental in advancing research in targeted cancer therapies. He has dedicated his career to improving cancer diagnosis and treatment through innovative approaches.

Collaborations

Je Yeol Cho has collaborated with notable colleagues, including Jae Tae Lee and Jung Soo Yu. These partnerships have enhanced his research efforts and contributed to the development of effective cancer treatment strategies.

Conclusion

Je Yeol Cho's innovative work in developing targeted peptides for cancer therapy showcases his commitment to advancing medical science. His contributions have the potential to significantly improve cancer diagnosis and treatment outcomes.